Eli Lilly and Boehringer Ingelheim's Jardiance against heart failure achieves breakthrough designation from FDA

Results from a phase III study with diabetes drug Jardiance are so promising that that the FDA has granted the medication breakthrough designation for fast tracking.
Photo: Mike Blake/REUTERS / X00030
Photo: Mike Blake/REUTERS / X00030

The US Food and Drug Administration (FDA) has designated the drug Jardiance from Eli Lilly and Boehringer Ingelheim the status 'breakthrough,' which fasttracks the application of the substance against a special type of heart failure, Eli Lilly informs in a statement. The FDA further explains the special status with the promising results from a phase III trial with Jardiance in the above indication.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading